# A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Study · id `cardio:ct-nct04075916` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04075916](<https://clinicaltrials.gov/study/NCT04075916>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04075916

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT04075916. Allocation not applicable; no masking; primary purpose treatment. Start 2021-06-22 (actual); primary completion 2025-07-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT04075916, source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)
- Started: 2021-06-22 (actual) (ClinicalTrials.gov record NCT04075916, source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)
- Primary completion: 2025-07-15 (actual) (ClinicalTrials.gov record NCT04075916, source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)
- Completion: 2026-02-25 (actual) (ClinicalTrials.gov record NCT04075916, source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04075916, source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04075916-2026-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
- Acronym: THINKER-NEXT
- Condition: End Stage Renal Disease
- Intervention (Drug): Epclusa
- Lead sponsor: University of Pennsylvania
- Lead sponsor class: OTHER
- Collaborator: Gilead Sciences
- Collaborator class: INDUSTRY
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: University of Pennsylvania (`cardio:org-university-of-pennsylvania`)
- Registry lists this organization as a collaborator: Gilead Sciences (`cardio:org-gilead-sciences`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: 32d7c0edf0f1277459c3f9796ea959d6ad784c0c3f2c561794e66c177206cac1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
